Compare Heron Therapeutics Inc (HRTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Yum China Holdings Inc trades at $42.83 (market cap $15.09B). The key difference: Yum China Holdings Inc is far larger — about 165× Heron Therapeutics Inc's market cap, and Yum China Holdings Inc pays a 2.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | YUMC | |
|---|---|---|
Market Cap | $91.46M | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $57.95 |
52-Week Low | $0.39 | $40.18 |
Enterprise Value | $189.36M | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
YUMC trades at $43.92, up 0.11% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $11.80B in 2025, and profitability remains solid with a 7.83% net margin. The acquisition of Pizza Hut China ownership is a strategic move expected to enhance margins.
The outlook is positive with strong analyst support (73.68% buy ratings), but risks include China's macroeconomic headwinds and competitive pressures. Valuation appears reasonable with a P/E of 16.81, suggesting potential for upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
